Blinatumomab in B-cell ALL | Maher Salamoon, MD | #EHA2025

Hello everyone, I'm Dr. Mahir Salamoun. I'm a hematologist oncologist. I'm working at Alberini University Cancer Center in Damascus, Syria. I make also consultations in Poland, Italy and other countries. So my main interest is AML, ALL, acute leukemias in general, and in Hotschfeld Lymphoma, including Maldimir Loma as well. This year in EHA, European Hematology Association, is taking place in Milan, Italy. This is the third day of the conference. So I have contributed nine research shedding light on several topics in hematologic malignancies. And the most important is treatment of ALL with new strategies. As you know, binatomumab is a new drug which is by specific antigen. It is targeting both CD19 and CD3 and it can be used in ALL treatment. Actually, it was approved by the FDA to treat patients with Philadelphia positive or Philadelphia negative, precursor B ALL or acute lymphoplastic leukemia. And it is also approved for patients with residual disease. So in my studies, I expanded this indication and I have run a trial showing the importance of binatomumab in the induction setting. So we have included patients with residual disease about less than equal or less than one percent of a blast in the bone marrow after the end of induction chemotherapy. So we check for residual disease by means of flosanometrics. So we have included patients after this induction are treated by binatomumab at the standard dose, which is nine micrograms per kilogram for seven consecutive days and 28 micrograms per kilogram beginning from day eight through day 28. So we have performed a bone marrow respiration after the end of treatment, the first cycle, I mean, of binatomumab. And we have demonstrated a very good response. I mean, a complete response by flosanometrics. So there was zero blast in the bone marrow in eight of 12 patients. However, the other four patients still demonstrating residual disease between 0.02 percent and 0.6 percent. They were treated with another cycle of binatomumab with the same schedule. So we have seen after the second cycle of binatomumab a complete response and a complete burgeon of bone marrow from blast. So by this way, we can prepare the patients to enter the consolidation therapy without with with, you know, a clean bone marrow, which can be reflected in a good response and consequently a good overall survival rate.